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Introduction
Cystic fibrosis (CF) is a disease caused by mutation in the gene encoding the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein. Although CF is a multi-system 
disorder, progressive lung disease is the most common cause of mortality. Decline in lung 
function is largely a result of structural lung damage associated with neutrophil-dominated 
inflammation and chronic pulmonary infections (1). Evidence of structural lung disease on 
chest computed tomography (CT), pulmonary inflammation and endobronchial infection (2, 
3) (4) have all been reported in the first months of life in infants diagnosed with CF 
following newborn screening (NBS), and often in the absence of respiratory symptoms (5, 
6). However, lung function is reported to be within normal limits for the majority of young 
infants diagnosed by (7–9), indicating a critical window of opportunity for intervention. 
While many new and exciting CF disease modifying agents are undergoing clinical trial 
evaluation (see (10) for review), including CFTR potentiators and correctors, clinical trials 
are difficult in patients younger than 5 years due a lack of age-appropriate clinical trial 
endpoints (ref 1. Davis SD, Brody AS, Emond MJ, Brumback LC, Rosenfeld M. Endpoints 
for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc. 2007 Aug 
1;4(4):418–30). This population, with less severe lung damage, are most likely to benefit 
from intervention with disease-modifying therapies and implementation of such therapies in 
infancy has the potential to change the prognosis for CF patients. As such, methods to assess 
early lung disease with the potential to serve as outcome measures for clinical trials are 
urgently needed. The increased emphasis on the detection and treatment of early CF lung 
disease over recent years (11) has driven the need for the development of sensitive, 
reproducible, and feasible outcome measures for quantifying mild lung disease in young 
children with CF, including advancements in infant and preschool lung function testing, 
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imaging of the chest, and the development of biomarkers; some of which will be reviewed 
herein as potential objective endpoints.
Lung function testing in infants and young children
As CF lung disease begins in the peripheral airways (see (12) for review), lung function tests 
that are sensitive to small airway dysfunction are required. While spirometry is the standard 
lung function measure in CF related clinical trials, it is generally considered insensitive to 
changes in small airway function (13–15) and cannot be reliably performed in young 
children. Techniques to measure lung function during infancy and the preschool years have 
developed over recent decades (16). In infancy their routine utilisation remains limited due 
to the requirement for sedation and the technical nature of infant lung function testing. In the 
preschool years lung function measures requiring tidal breathing are generally more 
successful than spirometry (17) as young children often lack the coordination for the forced 
exhalation, especially once low lung volumes are reached. We have reviewed the currently 
available or emerging lung function tests which have the potential to be applied in young 
children with CF.
Inert tracer gas washout
Inert tracer gas washout tests provide a measure of ventilation inhomogeneity (VI), over 
single or multiple breaths (SBW or MBW). The MBW involves tidal breathing of an inert 
tracer gas, generally helium (He) or sulfur hexafluoride (SF6), which is first “washed in,” 
then “washed out.” Alternatively, 100% oxygen (O2) can be used to “wash out” the resident 
nitrogen from the lungs, though this technique is not standard practice in infants due to the 
effects of 100% O2 on breathing pattern during infancy (18). A range of outcomes can be 
calculated, including the lung clearance index (LCI) and moment ratios, as well as indices 
representing the convection dependent inhomogeneity of the conducting airways (Scond) and 
the diffusion convection dependent inhomogeneity at the entry to the acinus (Sacin) derived 
from phase III slope analysis (See (19) for review). However, the most sensitive measure for 
detection of CF lung disease is not yet known.
The LCI is elevated in the majority of preschool and school-aged children with CF (13, 15, 
20) and is more sensitive than spirometry in this age group (13, 21). In addition, the LCI has 
been reported to increase with Pseudomonas aeruginosa infection in pre-school children (15) 
and to decrease following intravenous antibiotic therapy for pulmonary exacerbation (22), 
indicating that LCI may be a suit(23)able clinical tool for examining the response to 
therapeutic intervention in this age group (11, 24, 25). While LCI has recently been shown 
to be increased in the presence of Pseudomonas infection and airway inflammation (26), the 
LCI is less often abnormal in infants with CF (26, 27) and does not correlate with the 
presence of bronchiectasis on chest CT (23)
The SBW is not routinely used in the infant / preschool population due to the requirement of 
a vital capacity manoeuvre. However, recently, a SBW of a double tracer gas mixture (SF6 
and He) during tidal breathing (approximately 30 seconds) was shown to be feasible in 
healthy adults (28). In short, the gases are thought to distribute unequally in the lung 
periphery due to their marked differences in molecular mass resulting in a non-linear 
SIMPSON et al. Page 2













washout relationship which may be altered in small airway disease (28–30). If proven to be 
feasible and a sensitive marker of lung disease in the paediatric CF population, such a 
technique may eliminate the requirement of vital capacity manoeuvres and long washout 
times; though much groundwork remains regarding the sensitivity, potential confounders and 
appropriate modelling of the outcomes obtained from this test (28).
The inert gas washouts are potentially advantageous in that they can be performed during 
infancy without sedation (31) though their sensitivity for detecting small airways disease is 
unknown in this age group. In addition, differences in reference ranges between the N2 and 
SF6 washout methods will require specific reference equations for both methods from 
infancy to the school years for this technique to become a valuable clinical trial endpoint.
Raised volume rapid thoraco-abdominal compression technique (RVRTC)
RVRTC allows the measurement of spirometry in sedated infants. Briefly, the lungs are 
inflated to a pressure of 30 cm H2O after which a jacket fitted around the chest is rapidly 
inflated causing the lungs to empty to residual volume (32). The majority of young infants 
diagnosed with CF by NBS demonstrate measures of forced expiratory volume (FEV0.5), 
forced vital capacity (FVC) and forced expiratory flows (FEF) within the normal range (7–
9), with lung function deteriorating later in infancy (7, 8), particularly following infection 
with Staphylococcus aureus or Pseudomonas aeruginosa (8). Diminished lung function 
(FEF50) by RVRTC has been shown to track into school age in a small group of infants (33), 
though further longitudinal studies examining the long term impact of reduced RVRTC 
measures during infancy are required. In addition RVRTC has been used as an outcome 
measure in a study assessing the tolerability of inhaled hypertonic saline in infants (34–36) 
indicating that it may be suitable for monitoring lung function in response to intervention in 
infants with CF. In addition to the requirement of further work aimed at elucidating the 
relationships between RVRTC outcomes and spirometry outcomes at school age, routine use 
of RVRTC is limited by the requirement of sedation.
Forced Oscillation Technique (FOT)
The FOT measures input impedance of the respiratory system (Zrs) by applying pressure 
oscillations to the airway opening. The measured Zrs can be separated into respiratory 
system resistance (Rrs) and reactance (Xrs), which includes both elastic and inertive 
properties of the respiratory system. Measurement of Zrs at low frequencies (LFOT) allows 
the partitioning of lung function into components representing airway and parenchymal 
tissue mechanics (37) and as such offers significant potential for detection and monitoring of 
early (peripheral) lung disease in infants with CF. Despite this only one small study, 
demonstrating that several markers of inflammation correlate with LFOT outcomes, has 
been published in infants with CF (38). The lack of commercially available equipment, 
sufficient expertise, reference equations and the need for sedation significantly limit the 
ability of the LFOT to be used in large scale clinical trials.
The medium frequency FOT (see (39) for review) has been applied to young children with 
CF (≥2 years), with several authors concluding that this technique fails to adequately 
identify airway obstruction in CF (40–42). Gangell et al. reported higher Rrs and lower Xrs 
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in young children with CF than in healthy children; however, the majority of young children 
with CF had lung function within the normal range (43). Interestingly, children with current 
symptoms exhibited worse lung function when compared with asymptomatic children (43). 
As early CF lung disease is known to affect the peripheral lung, measures of Xrs or the area 
under the reactance curve (AX) may be more sensitive to changes in disease status than the 
traditionally reported Rrs. The technique is easy to perform and commercial equipment is 
available, as are comprehensive reference ranges (44). Further studies examining the 
relationship between FOT outcomes and structural lung damage, the presence of pulmonary 
infection and inflammation, and during interventions would be advantageous to determine 
this technique’s ability to be utilised as a clinical trial endpoint in preschool children.
Interrupter technique
The interrupter technique is based on the theory that mouth pressure and alveolar pressure 
will equilibrate when expiratory flow is interrupted, allowing the calculation of the 
interrupter resistance (Rint) (45). While some studies of preschool children with CF have 
demonstrated marginally higher Rint than their healthy counterparts (46), most studies have 
shown that Rint measurements do not distinguish health from disease (40, 47–50). In 
addition, no deterioration in Rint was noted in a longitudinal study despite radiographic 
worsening in preschool children with CF (49). Application of the interrupter technique is 
limited in CF as the mouth pressure and alveolar pressure are unlikely to have reached 
equilibration during the short occlusion time (typically 100 ms) in patients with airflow 
obstruction, leading to an underestimation of airway resistance (47). Therefore, this 
technique is unlikely to provide the required sensitivity for a clinical trial endpoint.
Plethysmography and plethysmography derived airway resistance
Plethysmography uses Boyles Law to measure intrathoracic gas volume during breathing 
efforts against a closed shutter. Since gas trapping is an early marker of respiratory 
dysfunction in infants with CF (5, 23) the use of this may provide valuable information 
about early lung disease. Previous studies of infants with CF have reported varying 
incidences of increased FRC measured by plethysmography (9, 51, 52) and demonstrated 
associations with pathogen density in lower airways at the time of clinically-indicated 
bronchoscopy (53). However, neither measurements of thoracic gas volume or airway 
conductance were able to detect differences in lung function between infants on continuous 
prophylactic antibiotics and those who received antibiotics when clinically indicated, with 
the mean values for both groups falling within normal limits (54). The use of 
plethysmography as a clinical trial endpoint is potentially limited by the variability of the 
end-expiratory volume defining FRC during infancy, particularly in the setting of obstructive 
lung disease. In addition, normal reference data using commercially available equipment is 
currently scarce.
Specific airway resistance (sRaw), corrected for total lung volume, is determined by 
simultaneously measuring airflow and the changes in whole body plethysmograph box 
volume with the shutter open, avoiding the need for the panting manoeuvre (55). Nielson et 
al., showed increased sRaw in young children with CF (40) however, algorithms applied to 
measures of sRaw vary in their thermal correction factors (56) and therefore are not 
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comparable between systems. Indeed, centre differences are apparent even with the same 
equipment (57) thus severely limiting the usefulness in multi-centre clinical trials.
Summary of lung function
Much progress in standardising lung function tests, which is essential for multi-centre 
collaborations, has been made in this age group over recent years (58, 59). However, 
measures of lung function in infants and preschool children continue to be limited by 
numerous factors including the need for sedation, lack of appropriate reference data, time 
and resource intensity as well as the apparent limited sensitivity of these tests in very young 
children with generally mild lung disease.
Imaging of the chest
In the absence of pathological specimens, imaging endpoints provide the most direct 
assessment of lung structure (60) and detect regional heterogeneity of disease (61). The 
pathological changes detected by imaging include bronchiectasis, or the pathological 
dilatation of airways, bronchial wall thickening, mucous plugging of airways by thickened 
secretions and air trapping, which is an indirect assessment of small airways disease, as well 
as parenchymal disease including atelectasis and consolidation (61). The three imaging 
modalities that have the greatest potential as endpoints for CF clinical trials are traditional 
chest radiography, chest computed tomography (CT) and lung magnetic resonance imaging 
(MRI) (61).
Chest Radiography
Several CF specific chest radiograph scoring systems have been developed and validated, 
and these correlate with clinical status and lung function (62, 63). Chest radiograph scores 
have been used as surrogates for lung disease in studies following infants from diagnosis 
after detection by newborn screening (64, 65), with radiographic progression evident in 85% 
of children by age 5 years (64). In preschool children, chest radiograph scores worsen over 3 
years despite stable lung function measured by the interrupter technique (49). However, mild 
structural changes that typify early CF lung disease in infancy are generally subtle on 
traditional chest radiography, which provides a two-dimensional representation of a complex 
three-dimensional structure. Further, early or mild bronchiectasis may not be identified on 
chest radiographs (60). The advantages of chest radiography lie in its ease of use and ready 
availability in most centres without a requirement for sedation, however its poor sensitivity 
for early bronchiectasis is likely to translate into a requirement for large sample sizes in 
clinical trials, and the focus therefore shifted to cross-sectional imaging endpoints with 
increased sensitivity to detect bronchiectasis.
Lung MRI
Lung MRI is a more recent imaging technique that does not involve ionising radiation 
exposure, and may therefore be appropriate for more frequent assessments of lung structure, 
particularly in older children and adults where sedation is not required (61). However, its use 
in early CF lung disease is in its infancy, and it remains to be validated as an appropriate 
endpoint for clinical trials in early childhood. Lung MRI lacks the spatial resolution of chest 
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CT (66), particularly in its ability to identify segmental and subsegmental healthy and 
diseased bronchi (67). Dilated subsegmental bronchi with minimal bronchial wall thickening 
or mucous plugging remain poorly visualised with standard techniques (68). As CF lung 
disease begins in the peripheral airways (12), it is critical that small airways disease is 
accurately assessed in studies examining early structural changes in infants and young 
children. In addition to difficulties directly visualising peripheral airways, standard lung 
MRI acquisition techniques poorly visualise air trapping (66, 69), an indirect measure of 
small airways obstruction, and while specialised sequences can improve detection rates, the 
sensitivity remains, at best, moderate (70). At this stage there are no studies linking 
structural changes detected by lung MRI to CF pathobiology and clinical endpoints. Further 
research demonstrating the ability of lung MRI to track disease progression in early 
childhood and predict clinical outcomes is required before lung MRI can be considered a 
valid endpoint for CF clinical trials commencing in infancy.
Chest CT
Chest CT has received the most attention as a potential endpoint for clinical trials in CF and 
is recognised for its ability to detect disease in asymptomatic children with normal chest 
radiographs and pulmonary function tests (61). The biggest advantage of chest CT as an 
endpoint to monitor disease progression in CF is its ability to objectively and directly assess 
changes in lung structure in patients of all ages, from infants soon after diagnosis (5) to 
patients with severe advanced lung disease awaiting lung transplant (71). Semi-quantitative 
CF specific CT scoring systems have consistently high within and between observer 
agreement (reviewed by de Jong et al (72)). Importantly, studies in younger (73) and older 
(74) children have demonstrated sensitivity to detect disease progression, with 
improvements seen in young children treated for pulmonary exacerbations (75). From early 
childhood to adolescence and adulthood, chest CT correlates with lung function (76–79), 
and in older children, chest CT is more sensitive to disease progression than traditional 
spirometric assessments of lung function (74). Chest CT is predictive of mortality (80), 
correlates with clinical endpoints including quality of life (81) and pulmonary exacerbations 
(82), and correlates with underlying CF pathobiology, including measures of inflammation 
and infection (4, 5, 73, 75).
Standardisation of lung volume during CT acquisition will facilitate comparisons of airways 
between infants or in the same child over time. Long et al. demonstrated that controlled 
ventilation limited slice chest CT scans in infants result in end-inspiratory images that are 
more sensitive to detect bronchiectasis than images acquired at end-expiration or during 
quiet breathing (83). Further studies are required to determine whether motion-free images 
obtained during quiet breathing in unsedated infants using modern ultrafast CT scanners 
provide images that are comparable over time for longitudinal studies.
The requirement for anaesthesia for lung volume control results in an increased incidence of 
atelectasis (84), although significant proportion of preschool children with CF undergoing 
unsedated chest CT also have some atelectasis (85). Anaesthesia related atelectasis can be 
reduced by a recruitment manoeuvre following induction of anaesthesia prior to acquisition 
of images, involving 10 deep inspirations to 30 cm H2O airway opening pressure (Regli and 
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Powers, unpublished observations). It is unclear whether a similar procedure is required for 
infants undergoing sedation rather than anaesthesia.
One of the argued limitations to chest CT as an endpoint is the risks associated with 
exposure to ionising radiation. One method to reduce exposure is to perform limited slice 
high resolution scans.. In school age children, limited slice approaches have poor sensitivity 
to detect disease extent for both airways disease (86) and air trapping (87, 88).
Modern chest CT scanners can perform full volumetric inspiratory and expiratory 
acquisitions in young children at relatively low doses equivalent to 2 or 3 PA/lateral chest 
xray series. A recent retrospective study supports arguments that scanning protocols 
currently suggested for imaging the lung in children with CF have a low risk of exposure 
related cancer. Using these data, the lifetime excess cancer risk for children scanned 
annually for the first 10 years of life is approximately 0.3%. However, we can expect that 
about 50% of children born now will die before the age of 50 years due to progressive lung 
disease.
Whether volumetric assessments of structural disease are more closely related to clinical 
features and underlying pathophysiology in young children is not known. From a clinical 
trials perspective, a volumetric approach is likely to reduce required sample sizes through 
improvements in sensitivity and precision, and should allow development of (semi-) 
automated analysis techniques to quantify disease. However, the standardisation of CT 
settings to achieve comparable images in terms of image quality and associated radiation 
exposures (92) will be important for multicentre studies involving chest CT.
To date, most studies using chest CT have employed a semi-quantitative CF specific CT 
scoring system. Tools to quantify structural lung disease in CF are in various stages of 
development (93–96), and (semi-) automated quantitative assessments of lung structure are 
likely to be preferred assessment tool in the future. Further research is required to determine 
the most appropriate tools to quantify early structural lung disease (gas trapping, bronchial 
wall thickening, bronchiectasis) and mucus plugging in early childhood, particularly 
assessing airway dimensions and air trapping, including formulation of appropriate reference 
ranges from corresponding normative data.
Summary of imaging
Chest CT is currently the imaging modality with the most promise as a robust clinical trials 
endpoint, particularly for the detection of airways disease including bronchiectasis, 
bronchial wall thickening and mucous plugging, and identification of air trapping as a 
surrogate measure of small airways obstruction. However, this technique is not without its 
limitations including the requirement for sedation to achieve lung volume control and 
concerns regarding radiation exposure. While there is sufficient data validating chest CT as 
an endpoint for clinical trials in CF, including studies from infancy, further research 
regarding acquisition techniques, assessment tools and standardisation for multicentre 
studies are required
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Biochemical biomarkers are a mainstay for monitoring clinical endpoints in many diseases. 
In contrast to lung function or imaging studies, biomarkers can assess the specific aspects of 
pathophysiology targeted by a potential therapeutic agent. However, identifying and 
measuring biomarkers of CF lung disease has proven challenging, particularly in infants and 
young children.
Blood
Measuring biomarkers in serum or plasma is perhaps the most common strategy for 
assessing endpoints in clinical trials, reflecting the relative ease with which blood based 
biomarkers can be obtained and evaluated. A large number of blood inflammatory markers 
are elevated relative in CF, including C-reactive protein (97–100), immunoglobulin G (98, 
101, 102), cytokines (99), tumor necrosis factor (103), and transforming growth factor β 
(104). Most studies of blood biomarkers in CF have demonstrated differences from healthy 
controls, cross-sectional relationships to other disease measures (97, 98) or changes with 
exacerbation (99, 100, 104, 105). However, an ideal clinical trial endpoint would be able to 
assess longitudinal changes from baseline lung disease and reflect both acute and chronic 
disease severity. A few studies suggest that some blood based biomarkers may meet these 
criteria. Wolter et al. demonstrated that median C-reactive protein decreased in patients 
treated with azithromycin and correlated with lung function (106), and Proesmans et al. 
found that serum IgG concentrations are predictive of lung function over time (101). 
Similarly, Oliero et al. found lipid signatures predictive of longitudinal changes in lung 
function (107). While promising, these markers require further study to assess their 
reliability and validity as well as their ability to detect meaningful changes in response to 
therapy. One significant concern for any blood based inflammatory biomarker of the fact that 
non-pulmonary inflammation could impact biomarker concentrations and reduce the 
specificity of the biomarker for lung disease. Furthermore, because most studies have 
focused on older children and adults, it is unclear whether these inflammatory markers 
would be effective in young children who have correspondingly less disease.
Urine
Urine is attractive as a source of biomarkers since it can be collected non-invasively, though 
collection can be more challenging in younger children. There is some evidence that urinary 
biomarkers may be useful in CF lung disease. For example, urinary concentrations of the 
breakdown products of elastin, desmosine and isodesmosine, correspond to neutrophil 
elastase activity and reflect neutrophilic airway inflammation (108). Although there is 
evidence that changes in these compounds may reflect therapeutic effects (109, 110), there is 
currently insufficient evidence to recommend using such markers as outcome measures in 
young children.
Airway
In theory, the best way to track disease processes occurring in the lung is to obtain samples 
directory from the airway. This potential has been well demonstrated through analyses of 
sputum, and several sputum biomarkers appear to track lung inflammation and have 
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potential as clinical trial endpoints (111). However, sputum biomarkers are of limited utility 
in the youngest children with CF, who cannot generally produce sputum. As sputum markers 
have been reviewed extensively elsewhere (112) and are more relevant to an older 
population, they are not considered further in this review.
In younger children, flexible bronchoscopy with bronchoalveolar lavage (BAL) represents 
the primary means to obtain airway secretions for analysis (113). Lower airway 
microbiology can be assessed through analysis of BAL fluid, as can numerous inflammatory 
markers including neutrophil counts, neutrophil elastase, interleukin-8 and other cytokines, 
and others (3, 4, 114–117). Many of these inflammatory markers correlate with other aspects 
of disease severity including respiratory pathogens (118), radiologic findings (4, 73, 75), and 
outcomes from infant lung function testing (3, 117). However, bronchoscopy has several 
significant limitations. CF lung disease is heterogeneous, and the location of lavage can 
significantly influence measures of disease markers (75, 119, 120). Furthermore, 
bronchoscopy requires considerable time, expertise, and expense and entails risks of 
sedation as well as possible pyrexia, or bronchoconstriction. As a result of these limitations, 
most studies of BAL fluid biomarkers have relied on clinically indicated procedures, and 
there is a paucity of data on longitudinal validity, reliability, and sensitivity to treatment 
effects. Some of these issues are being addressed through the AREST CF protocol, which 
includes annual bronchoscopy with BAL at clinical baseline in the first six years of life (4). 
These studies are providing critical data on the longitudinal variation in common BAL fluid 
biomarkers including cell counts, neutrophil elastase, and IL-8 (4, 73)
Although the utility of BAL fluid biomarkers to longitudinally assess CF lung disease 
remains unproven, bronchoscopy has proven useful for assessing other clinically relevant 
endpoints. For example, Gibson et al. utilized eradication of Pseudomonas infection in BAL 
fluid cultures as a primary outcome measure in their assessment of inhaled tobramycin 
(121), and others have used BAL to assess concentrations of inhaled antimicrobials (122) 
and other drugs (123) in the lower airway. Thus, bronchoscopy with BAL does currently 
have a role in clinical trials, though mainly in early phase studies for targeted endpoints.
Exhaled Breath
Exhaled breath contains a number of volatile and non-volatile compounds, including many 
that are effective biomarkers in sputum or bronchoalveolar lavage (124). Non-volatile 
markers can be collected as exhaled breath condensate (EBC), and since collection only 
requires the subject to exhale through a chilled tube, obtaining EBC can be simple and 
completely non-invasive even in young children. However, EBC is mostly condensed water 
vapour with a small and highly variable fraction of airway secretions, complicating analysis 
of non-volatile EBC biomarkers. Therefore, extremely sensitive methods are needed to 
assess the low concentrations of biomarkers found in EBC, ideally coupled with some 
method to control for variable dilution (125, 126).
Despite these complications, studies have identified several EBC biomarkers elevated in CF 
including multiple cytokines (127–130), 8-isoprostane (127, 131), nitrates (127, 132), 
leukotrienes (133), and purines (117, 134) EBC pH has also been shown to be decreased in 
subjects with CF (135–137). EBC pH, leukotrienes and purines have been shown to track 
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changes in treatment of CF exacerbations (133–137). However, application of EBC 
biomarkers as clinical endpoints will require further efforts to explore the longitudinal 
variability and sensitivity to treatment effects.
Applying EBC methodology to the youngest children poses additional challenges, since 
infants and young preschoolers cannot voluntarily exhale through the EBC collection tube. 
Several studies have demonstrated that EBC can be collected from infants sedated for lung 
function testing (138, 139), and a recent investigation demonstrated that EBC purines 
correlate with infant lung function measures (140). Further study will be required to 
determine whether the EBC approach can be successfully applied to infants and young 
children.
While EBC is ideal for assessing traditional, non-volatile biomarkers, exhaled breath also 
contains a number of volatile compounds that could potentially serve as disease markers 
(141, 142). Such biomarkers have appeal, since they can potentially be measured at the point 
of care using devices such as an ‘electronic nose’ (143). For now, exhaled volatile markers 
remain at a fairly early stage of development and require further study before determination 
of clinical applicability.
Summary of biomarkers
Applying biochemical biomarkers of CF lung disease in young children holds great promise 
but poses considerable challenges. At this time, there are no biomarkers proven as a 
endpoints for clinical trials in young children with CF. Ongoing and future studies assessing 
the validity, reliability, and sensitivity to treatment effects are necessary to develop such 
biomarkers into clinically useful tools. Because biochemical biomarkers can assess unique 
aspects of disease pathophysiology, they are likely to serve as a complementary role to lung 
function and imaging studies in clinical trials.
Conclusions
The ideal endpoint in any clinical trial needs to be accurate, precise and reliable, with 
minimal risk and across all ages, easy to perform, and be inexpensive (144). Over the past 10 
years, much progress has been made in developing infant and preschool lung function tests, 
chest imaging modalities and biomarkers as potential clinical trial endpoints for the 
youngest patients with CF. However, a common limitation across all of these potential 
targets for clinical trial endpoints is the requirement for sedation or anaesthesia in our 
youngest patients. While paediatric anaesthesia is considered to be fairly safe (145, 146), 
there are some concerns about potential neurotoxicity of sedative and anaesthetic agents 
(147). A reasonable approach is to minimise unnecessary exposure to procedures requiring 
sedation where possible, however the theoretical risks of neurotoxicity must be weighted 
against the potential advantages of sedation for lung function measures, lung volume control 
for chest CT and bronchoscopic collection of BAL fluid in a life limiting disease.
CT scans are particularly promising because of their ability to detect early structural lung 
changes. In fact, this year, the first study to determine whether an early intervention can 
prevent structural lung disease (COMBAT CF: clinicaltrials.gov identifier NCT01270074) in 
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a newborn-screened population will commence. This pioneering study will use chest CT as a 
trial endpoint to investigate whether azithromycin use from diagnosis reduces the prevalence 
of CT-detected bronchiectasis at age 3 years. There is no doubt that this trial will further our 
knowledge on the challenges of standardised operating procedures for multicentre trials, 
agreement on the most appropriate scoring systems for young children, and a better 
understanding of the sensitivity and specificity of chest CT to treatment effects.
Newborn screening for CF affords the opportunity to intervene before lung function 
declines; however, a distinct lack of appropriate outcome measures has severely limited the 
availability of clinical trials in this age group. While currently in various stages of 
development, the potential candidates reviewed herein may come to play a role in infant 
and/or preschool clinical trial endpoints. As none of these techniques is without limitation, 
and it remains unknown what treatment effects are achievable in this population with mild 
lung disease, it is likely that future trials in the youngest CF patients will require a 
combination of structural, functional and bronchoscopic outcomes to successfully detect and 
monitor CF lung disease over the course of an intervention.
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